FDMT
Live chart
What they do
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
For information only · Important disclosures
Grades vs sector
No sector grades for FDMT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.74 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-4.09 vs trailing $-2.60. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Altman Z-score 2.4 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $85.2M | $-140.1M | $-109.6M |
| 2024 | $37.0K | $-160.9M | $-138.4M |
| 2023 | $20.7M | $-100.8M | $-78.6M |
| 2022 | $3.1M | $-107.5M | $-98.2M |
| 2021 | $18.0M | $-71.3M | $-78.2M |
| 2020 | $13.6M | $-56.7M | $-51.9M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +200.9%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -1.02 | -1.04 | -2.3% |
| 2026-05-07 | -1.00 | -1.01 | -1.4% |
| 2026-03-18 | -0.53 | 0.43 | +181.4% |
| 2025-11-10 | -0.98 | -1.01 | -2.8% |
| 2025-08-11 | -0.69 | -0.98 | -41.4% |
| 2025-05-08 | -0.86 | -0.86 | +0.2% |
| 2025-02-28 | -0.84 | -0.90 | -7.4% |
| 2024-11-13 | -0.70 | -0.79 | -12.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $3.8M | +25106.7% |
| 2026-03-31 | $3.0M | – |
| 2025-12-31 | $85.1M | – |
| 2025-09-30 | $90.0K | – |
| 2025-06-30 | $15.0K | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$21.0K
$3.7K
$750.2K
$22.3K
$811.0K
$8.2K
$425.7K
$662.6K
$19.9K
$19.6K
$274.6K
$124.7K
Stats refreshed 2026-10-21 12:33:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026